207 related articles for article (PubMed ID: 36930833)
1. FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer.
Wu Y; Li Z; Wedn AM; Casey AN; Brown D; Rao SV; Omarjee S; Hooda J; Carroll JS; Gertz J; Atkinson JM; Lee AV; Oesterreich S
Mol Cancer Res; 2023 Jun; 21(6):591-604. PubMed ID: 36930833
[TBL] [Abstract][Full Text] [Related]
2. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
3. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
Li Z; Wu Y; Yates ME; Tasdemir N; Bahreini A; Chen J; Levine KM; Priedigkeit NM; Nasrazadani A; Ali S; Buluwela L; Arnesen S; Gertz J; Richer JK; Troness B; El-Ashry D; Zhang Q; Gerratana L; Zhang Y; Cristofanilli M; Montanez MA; Sundd P; Wallace CT; Watkins SC; Fumagalli C; Guerini-Rocco E; Zhu L; Tseng GC; Wagle N; Carroll JS; Jank P; Denkert C; Karsten MM; Blohmer JU; Park BH; Lucas PC; Atkinson JM; Lee AV; Oesterreich S
Cancer Res; 2022 Apr; 82(7):1321-1339. PubMed ID: 35078818
[TBL] [Abstract][Full Text] [Related]
4. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
[TBL] [Abstract][Full Text] [Related]
5. FOXA1 is a key determinant of estrogen receptor function and endocrine response.
Hurtado A; Holmes KA; Ross-Innes CS; Schmidt D; Carroll JS
Nat Genet; 2011 Jan; 43(1):27-33. PubMed ID: 21151129
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
7. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
[TBL] [Abstract][Full Text] [Related]
8. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
[TBL] [Abstract][Full Text] [Related]
9. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility.
Theodorou V; Stark R; Menon S; Carroll JS
Genome Res; 2013 Jan; 23(1):12-22. PubMed ID: 23172872
[TBL] [Abstract][Full Text] [Related]
10. High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer.
Fu X; Pereira R; Liu CC; De Angelis C; Shea MJ; Nanda S; Qin L; Mitchell T; Cataldo ML; Veeraraghavan J; Sethunath V; Giuliano M; Gutierrez C; Győrffy B; Trivedi MV; Cohen O; Wagle N; Nardone A; Jeselsohn R; Rimawi MF; Osborne CK; Schiff R
Cell Rep; 2023 Aug; 42(8):112821. PubMed ID: 37467106
[TBL] [Abstract][Full Text] [Related]
11. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
Jing X; Liang H; Hao C; Hongxia L; Cui X
Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
[TBL] [Abstract][Full Text] [Related]
12. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.
Joosten SEP; Gregoricchio S; Stelloo S; Yapıcı E; Huang CF; Yavuz K; Donaldson Collier M; Morova T; Altintaş UB; Kim Y; Canisius S; Moelans CB; van Diest PJ; Korkmaz G; Lack NA; Vermeulen M; Linn SC; Zwart W
Genome Res; 2024 May; 34(4):539-555. PubMed ID: 38719469
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 represses the molecular phenotype of basal breast cancer cells.
Bernardo GM; Bebek G; Ginther CL; Sizemore ST; Lozada KL; Miedler JD; Anderson LA; Godwin AK; Abdul-Karim FW; Slamon DJ; Keri RA
Oncogene; 2013 Jan; 32(5):554-63. PubMed ID: 22391567
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
18. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.
Li Z; McGinn O; Wu Y; Bahreini A; Priedigkeit NM; Ding K; Onkar S; Lampenfeld C; Sartorius CA; Miller L; Rosenzweig M; Cohen O; Wagle N; Richer JK; Muller WJ; Buluwela L; Ali S; Bruno TC; Vignali DAA; Fang Y; Zhu L; Tseng GC; Gertz J; Atkinson JM; Lee AV; Oesterreich S
Nat Commun; 2022 Apr; 13(1):2011. PubMed ID: 35440136
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
[TBL] [Abstract][Full Text] [Related]
20. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
Fu X; Pereira R; De Angelis C; Veeraraghavan J; Nanda S; Qin L; Cataldo ML; Sethunath V; Mehravaran S; Gutierrez C; Chamness GC; Feng Q; O'Malley BW; Selenica P; Weigelt B; Reis-Filho JS; Cohen O; Wagle N; Nardone A; Jeselsohn R; Brown M; Rimawi MF; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2019 Dec; 116(52):26823-26834. PubMed ID: 31826955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
